Breaking News

A symptom of dementia leads to a burst of artistic creativity

August 10, 2023
Reporter, Morning Rounds Writer
Good morning. Don't miss Bree Iskandar's fascinating report on an unusual feature of dementia that in a small fraction of people prompts an explosion of artistic creativity.

Health tech

Telehealth companies are driving a large share of weight loss drug prescriptions, claims data hint


As the demand for obesity medications climbs ever higher, so does the popularity of online routes to getting them. A new Trilliant Health analysis of claims data commissioned by STAT suggests that collectively, telehealth companies — many marketing cash-pay options directly to consumers — could make up nearly half of all insurance claims for GLP-1 prescriptions. Here's how the math works: Among the 3.6 million people with a prescription claim for a GLP-1 drug, 53% of patients also had a claim for a medical visit within three days.

That hints that the other 47% of patients filing insurance claims  — around 1.7 million Americans — likely didn't see a doctor but got the drug from a direct-to-consumer telehealth company. That worries the doctors STAT's Katie Palmer talked to because the drugs have both serious side effects and a significant impact on body mass. Plus skilled obesity specialists are in shortage. Read more.


drug pricing

Genentech weighs delaying cancer therapy following drug pricing law

There have been lawsuits, from pharma companies and the trade group PhRMA. There have been op-eds. They oppose the part of last year's Inflation Reduction Act that allows Medicare to negotiate prices, arguing it will stifle R&D. But this stands out: Genentech CEO Alexander Hardy told STAT's Rachel Cohrs that the provision could make the company delay research on how a drug designed for prostate cancer might also help in ovarian cancer, based on the time allowed before price negotiation can begin.

"Normally, we would develop it in a fast market approach for ovarian cancer. That's the shortest path to patients … but that is a much smaller indication than prostate cancer, which would take three years longer," he said. "Do we go with the initial indication being prostate cancer and then hold off on the development and the approval [for] ovarian [cancer] because the clock will be started with prostate?" Read the full interview here.


global health

'Everybody in the world should be a sentinel': what disease surveillance could look like

7F5A5113-copyCourtesy Pardis Sabeti

Lassa fever has been simmering in West Africa for hundreds of years. The deadly hemorrhagic illness often looks like yellow fever, malaria, or typhoid, but it wasn't until 15 years ago that diagnosis and treatments for it arrived in Nigeria. That happened because of two geneticists working together from worlds apart. Christian Happi (above, center) at Redeemer's University and Pardis Sabeti (above, second from right) at the Broad Institute also want to do better across Africa.

Their mission with the disease surveillance system Sentinel is to overcome three obstacles: pathogens are detected late, transmitting data takes too long, and health care workers don't have the resources they need. If their vision succeeds worldwide, it could prevent the next pandemic before it starts, Happi said. "Everybody in the world should be a sentinel, a sentinel not only for his own immediate community, for his own country — but a sentinel for the globe." STAT's Simar Bajaj and Abdullahi Tsanni have more on the Sentinel project.



Closer Look

For a few with dementia, artistic expression explodes

Courtesy Ann Adams/UCSF Memory and Aging Center 

Of all the ways the brain is bewildering, this ranks among the oddest. And perhaps the most beautiful. For a small percentage of people with frontotemporal dementia, as the neurodegenerative disease saps them of their ability to reason or even to speak, they have an explosion of artistic creativity. A flourishing interest in art can show up as a sudden affinity, a dramatic change in the type or style of art they produce, or simply the enormous amount of time dedicated to art. 

The brain disease can manifest in sometimes remarkably different ways, depending on which side of the brain it starts. Anne Adams' artwork (above) reflected her passions. After FTD robbed the biologist of her speech, she painted symmetrical patterns of biological creatures, a color-by-number representation of the first 1,500 digits of pi in honor of her mathematician husband, and visual interpretations of classical music. STAT's Bree Iskandar has more.


long covid

How SARS-CoV-2 disrupts mitochondria could explain some of long Covid, study suggests

Scientists know the virus that causes Covid has tentacles reaching throughout the body, but a new study maps out just how SARS-CoV-2 hijacks mitochondria, the power plants in our cells, and may lead to long Covid. Building on previous work, the Science Translational Medicine paper defines the genetic mechanism damaging mitochondria in the lungs, heart, liver, kidneys, and brain. Senior author Douglas Wallace wasn't surprised to see this activity, but "we were amazed at how sophisticated the virus is in achieving that goal." 

To Eric Topol of Scripps, that cements the case for mitochondria as one of the root causes of long Covid and its symptoms from fatigue to brain fog. (He reminded me Wallace is a world authority on mitochondria, so "this is not just some kind of rookie group. This is the all-stars.") What's next? "We have hypothesized that that is an important factor in long Covid," Wallace told me. "But we don't have the funds to pursue that research." Read more.


pandemic

WHO says the risk is low from the latest SARS-CoV-2 subvariant spreading in the U.S.

Here's a Covid update from STAT's Helen Branswell: A SARS-CoV-2 subvariant that is gaining ground in the U.S. has been designated a variant of interest by the WHO, which bumped up the Omicron-based sublineage EG.5 yesterday from its previous status as a variant under monitoring. While EG.5 seems to have a growth advantage over previous versions of the virus, it does not appear to be more dangerous. For example, there's no evidence it triggers more severe disease, the report said. And it has the same amino acid profile as XBB.1.5, which this fall's Covid boosters target.

"Based on the available evidence, the public health risk posed by EG.5 is evaluated as low at the global level," the agency's risk assessment stated, though it acknowledged that some of its conclusions about EG.5 are based on sparse evidence because global Covid surveillance has declined dramatically. It's one of several subvariants currently circulating in different regions. "There is no one variant that is dominant anywhere," said Maria Van Kerkhove, the WHO's team lead for Covid, who urged countries to continue to sequence and submit data on SARS-2 viruses.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • CDC director overhauls leadership of center that oversaw response to Covid-19, STAT
  • How a controversial U.S. drug policy could be harming cancer patients worldwide, Nature

  • Unstoppable: This doctor has been investigated at every level of government. How is he still practicing? ProPublica

  • She invited four people over for lunch. A week later, three were dead, Washington Post

  • Study shows autistic people are more likely to engage in self-harm — but not because of autism, STAT
  • After 25 years of hype, embryonic stem cells are still waiting for their moment, Tech Review

Thanks for reading! More tomorrow,


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments